Aradigm Corporation (NASDAQ:ARDM) Files An 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a RegistrantItem 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
| (1) |
Incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K/A (No. 001-36480) filed on April28, 2016. |
| (2) |
Incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K (No. 001-36480) filed on April23, 2018. |
| (3) |
Incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K (No. 001-36480) filed on April18, 2018. |
| * |
Filed with this Current Report on Form 8-K. |
4
ARADIGM CORP ExhibitEX-4.3 2 d583165dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 FACE OF PIK NOTE THIS SECURITY AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS SECURITY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,…To view the full exhibit click here
About Aradigm Corporation (NASDAQ:ARDM)
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.